The Target Newsletter: Management of early-stage non-small cell lung cancer with SABR (EM1509A)

Non-small cell lung cancer (NSCLC) has had the highest rate of cancer incidence and patient deaths in the U.S. for decades. Due to poor health/comorbidities, many patients are not able to receive the standard of care for early-stage disease, namely, surgical resection with lobectomy. As an alternative, some of these patients have been treated with standard fractionation radiation, traditionally to doses of 60-70 Gy over six to seven weeks, with limited durable tumor control. The inadequacy in treatment response has led radiation oncologists to consider other ways to treat these patients. Many have moved toward stereotactic body radiation therapy (SBRT)—also known as stereotactic ablative radiotherapy (SABR)—in treating early-stage primary NSCLC.

 

Management of early-stage non-small cell lung cancer with SABR (EM1509A) - Article (PDF)

Target Audience

This activity is targeted to radiation oncologists, medical oncologists, surgical oncologists, neuro-oncologists, family medicine, generalists, radiation therapists, residents, and medical students.  

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Identify the types of patients and lung lesions suitable for SBRT as a curative treatment
  • Describe the benefits that SABR can offer over conventional radiation treatment in the management of early-stage NSCLC
  • Describe the evolution of treatment leading to the use of SBRT for early-stage NSCLC
Course summary
Available credit: 
  • 0.50 AMA
  • 0.50 Attendance
Course opens: 
02/01/2016
Course expires: 
02/28/2017
Cost:
$0.00
Part of: 
The Target Newsletter

Activity Director

Lucien Nedzi, M.D.
Associate Professor of Radiation Oncology
UT Southwestern Medical Center
Dallas, TX
Disclosure: Department of Radiation Oncology has financial relationship with Accuray Inc., the company that produces the CyberKnife

Co-Director and Editor

Dee Hill
Program Coordinator / Radiation Oncology
UT Southwestern Medical Center
Dallas, TX
Disclosure: Department of Radiation Oncology has financial relationship with Accuray Inc., the company that produces the CyberKnife

Faculty Writer

Puneeth Iyengar, M.D., Ph.D.,

Assistant Professor of Radiation Oncology
UT Southwestern Medical Center
Dallas, TX
Disclosure: No relevant financial relationships to disclose.

 

Accreditation Statement

The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

How to Access Course Materials

  • Create an account in EthosCE, online learning management system, by selecting the "create an account" link at the bottom of the page or "log-in" to your existing account.
  • Return to this course page and select "Take Course" at the bottom of the page.

Available Credit

  • 0.50 AMA
  • 0.50 Attendance

Price

Cost:
$0.00
Please login or create an account to take this course.